Humacyte, Inc. (NASDAQ:NASDAQ:HUMA) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ETCompany ParticipantsLauren Marek - LifeSci Advisors Laura...
In the future, dental bone graft substitutes are expected for significant developments. Innovations in biomaterials & surgical techniques will improve...
Humacyte's stock price has recently been on an impressive bull run. Read why I could see HUMA achieving a billion-dollar valuation within the next 12 months.
Humacyte, Inc. (NASDAQ:NASDAQ:HUMA) Q1 2024 Earnings Conference Call May 10, 2024 8:00 AM ETCompany ParticipantsTom Johnson - Investor Relations, LifeSci...
-Biologics License Application (BLA) for HAV™ Accepted by FDA- -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA date set for August...
Operator: Good morning, ladies and gentlemen, and welcome to the Humacyte 2023 Fourth Quarter Year-End Results Conference Call. Currently, all participants are in a listen-only mode.
-Biologics License Application (BLA) for HAV™ Accepted by FDA on February 8, 2024- -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA...
Alpha Healthcare Acquisition Corp. III (ALPA) shareholders have approved a proposed merger with allogeneic biomaterials developer Carmell Therapeutics. Read more here.
-- Enrollment Nearing Completion in Human Acellular Vessel™ (HAV™) Phase 2/3 Trial in Vascular Trauma and Phase 3 Trial in Arteriovenous (AV) Access in...